Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Needle-free Gardasil delivery in adolescents
NCT06142461Phase 2Withdrawn
- Sponsor
- PharmaJet
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of qHPV vaccine in human papillomavirus infection (3 arms), sponsored by PharmaJet. Primary endpoints: Safety of fractional dose intradermal administration of Gardasil using PharmaJet Tropis Needle-Free Injection System, Immunogenicity of fractional dose intradermal administration of Gardasil using PharmaJet Tropis Needle-Free Injection System and 2 more. Planned start May 2024; status: withdrawn.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06142461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06142461.